Cogent Biosciences is a biotechnology company developing real solutions to treat genetically driven diseases. With a focus on the design of rational precision therapies, we are leveraging validated biology to address the true underlying drivers of disease and provide real hope for patients. We have ongoing clinical research programs in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST).
Cogent is focused on developing novel precision therapies to treat a broad range of patients with unmet medical needs. Lead program, bezuclastinib, is being developed for Systemic Mastocytosis and Gastrointestinal Stromal Tumors. In addition, the Research Team is developing a portfolio of novel therapies initially targeting ErbB2 and FGFR2.